We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

3037:TWSEUnimicron Technology Corp. Analysis

Data as of 2026-07-21 - not real-time

NT$825.00

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Unimicron is trading at TWD 825, comfortably above the calculated support of TWD 747 but still under short‑term averages of SMA‑20 914 and SMA‑50 933, signaling a short‑term pull‑back. The RSI of 44 and a bearish MACD histogram reinforce a neutral‑to‑bearish bias, while volume is on a decreasing trend, suggesting waning buying pressure. On the valuation side, the stock’s trailing P/E of 118 dwarfs the industry average of 33, and the DCF‑derived fair value of TWD 279 is far below the market price, indicating a substantial overvaluation gap. Despite this, the company’s fundamentals show a robust 24.5% revenue growth, a forward EPS surge to TWD 32.78, and a forward P/E of 25, hinting at strong earnings momentum ahead. However, the free cash flow is negative and the dividend yield sits at a modest 0.26% with a 21% payout, raising questions about cash sustainability. High beta (≈1.5‑2.1) and 30‑day volatility near 90% add to the risk profile, while the broader electronics‑components sector carries cyclical and geopolitical exposure.
In the medium‑term, analysts project a target price around TWD 1,165, implying a potential upside of roughly 40% if the market re‑prices the growth story. Yet, the current price premium and macro‑risk factors suggest that a correction may precede any upside realization. Long‑term investors may find the company attractive for its growth trajectory and solid cash reserves, provided they can tolerate valuation compression and the volatility inherent to the high‑beta, technology‑heavy exposure.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • price below short‑term SMAs
  • bearish MACD and RSI near neutral
  • decreasing trading volume

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • significant forward earnings growth
  • substantial valuation gap to DCF fair value
  • high beta and volatility

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • strong revenue growth and earnings outlook
  • large cash balance despite debt
  • potential for valuation re‑rating after price correction

Key Metrics & Analysis

Financial Health

Revenue Growth24.50%
Profit Margin7.79%
P/E Ratio118.2
ROE11.00%
ROA2.03%
Debt/Equity49.69
P/B Ratio11.6
Op. Cash FlowNT$17.8B
Free Cash FlowNT$-336875136
Industry P/E32.9

Technical Analysis

TrendNeutral
RSI43.7
SupportNT$747.00
ResistanceNT$1,115.00
MA 20NT$914.70
MA 50NT$933.10
MA 200NT$496.53
MACDBearish
VolumeDecreasing
Fear & Greed Index90.2

Valuation

Fair ValueNT$278.67
Target PriceNT$1,164.31
Upside/Downside41.13%
GradeOvervalued
TypeGrowth
Dividend Yield0.26%

Risk Assessment

Beta1.52
Volatility90.41%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.